These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 34545668)

  • 1. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Karagiannis T; Kakotrichi P; Michailidis T; Liakos A; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2022 Jan; 24(1):106-114. PubMed ID: 34545668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials.
    Musso G; Gambino R; Cassader M; Paschetta E
    BMJ; 2019 Apr; 365():l1328. PubMed ID: 30967375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral semaglutide for type 2 diabetes: A systematic review and meta-analysis.
    Avgerinos I; Michailidis T; Liakos A; Karagiannis T; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Mar; 22(3):335-345. PubMed ID: 31637820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years.
    Liu XY; Zhang N; Chen R; Zhao JG; Yu P
    J Diabetes Complications; 2015; 29(8):1295-303. PubMed ID: 26365905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of sotagliflozin in patients with type II diabetes mellitus and chronic kidney disease: a meta-analysis of randomized controlled trials.
    Dos Santos Borges R; de Oliveira Almeida G; Alves VFC; Nienkotter TF; Bertoli ED; Simões E Silva AC
    J Nephrol; 2024 May; 37(4):881-896. PubMed ID: 38141092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of bexagliflozin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Pasqualotto E; Figueiredo Watanabe JM; Gewehr DM; da Silva Maintinguer R; van de Sande-Lee S; de Araujo GN; Leal FS; Pinheiro CEA
    Diabetes Obes Metab; 2023 Jul; 25(7):1794-1802. PubMed ID: 36929659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    Bhatt DL; Szarek M; Pitt B; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Inzucchi SE; Kosiborod MN; Cherney DZI; Dwyer JP; Scirica BM; Bailey CJ; Díaz R; Ray KK; Udell JA; Lopes RD; Lapuerta P; Steg PG;
    N Engl J Med; 2021 Jan; 384(2):129-139. PubMed ID: 33200891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
    Mantsiou C; Karagiannis T; Kakotrichi P; Malandris K; Avgerinos I; Liakos A; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2020 Oct; 22(10):1857-1868. PubMed ID: 32476254
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of adding sotagliflozin, a dual sodium-glucose co-transporter (SGLT)1 and SGLT2 inhibitor, to optimized insulin therapy in adults with type 1 diabetes and baseline body mass index ≥ 27 kg/m
    Danne T; Edelman S; Frias JP; Ampudia-Blasco FJ; Banks P; Jiang W; Davies MJ; Sawhney S
    Diabetes Obes Metab; 2021 Mar; 23(3):854-860. PubMed ID: 33289297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular safety and efficacy of metformin-SGLT2i versus metformin-sulfonylureas in type 2 diabetes: systematic review and meta-analysis of randomized controlled trials.
    Gebrie D; Getnet D; Manyazewal T
    Sci Rep; 2021 Jan; 11(1):137. PubMed ID: 33420333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sotagliflozin: a dual sodium-glucose co-transporter-1 and -2 inhibitor for the management of Type 1 and Type 2 diabetes mellitus.
    Sims H; Smith KH; Bramlage P; Minguet J
    Diabet Med; 2018 Aug; 35(8):1037-1048. PubMed ID: 29637608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.
    Toyama T; Neuen BL; Jun M; Ohkuma T; Neal B; Jardine MJ; Heerspink HL; Wong MG; Ninomiya T; Wada T; Perkovic V
    Diabetes Obes Metab; 2019 May; 21(5):1237-1250. PubMed ID: 30697905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL; Szarek M; Steg PG; Cannon CP; Leiter LA; McGuire DK; Lewis JB; Riddle MC; Voors AA; Metra M; Lund LH; Komajda M; Testani JM; Wilcox CS; Ponikowski P; Lopes RD; Verma S; Lapuerta P; Pitt B;
    N Engl J Med; 2021 Jan; 384(2):117-128. PubMed ID: 33200892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials.
    Wu J; Zhao X; Chen H; Zhu S
    J Diabetes Complications; 2022 Dec; 36(12):108352. PubMed ID: 36370667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of the dual sodium-glucose co-transporter-1 and -2 inhibitor sotagliflozin on renal outcomes in type 1 diabetes and type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Bantounou MA; Sardellis P; Thuemmler R; Black Boada D; Kaczmarek J; Mahmood R; Plascevic J; Philip S
    Diabetes Obes Metab; 2024 Feb; 26(2):710-720. PubMed ID: 38031239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis.
    Avgerinos I; Manolopoulos A; Michailidis T; Kitsios K; Liakos A; Karagiannis T; Dimitrakopoulos K; Matthews DR; Tsapas A; Bekiari E
    Diabetes Obes Metab; 2021 Mar; 23(3):822-831. PubMed ID: 33300282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
    Cherney DZI; Ferrannini E; Umpierrez GE; Peters AL; Rosenstock J; Carroll AK; Lapuerta P; Banks P; Agarwal R
    Diabetes Obes Metab; 2021 Dec; 23(12):2632-2642. PubMed ID: 34338408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
    Cariou B; Charbonnel B
    Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a sodium-glucose co-transporter-2 inhibitor versus placebo as an add-on therapy for people with type 2 diabetes inadequately treated with metformin and a dipeptidyl peptidase-4 inhibitor: a systematic review and meta-analysis of randomised controlled trials.
    De Buitléir C; O' Connor E; Satti MM; Shaw J; Liew A
    Diabet Med; 2021 Feb; 38(2):e14409. PubMed ID: 32979231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.